David G. McLeod

17.8k total citations · 2 hit papers
271 papers, 13.3k citations indexed

About

David G. McLeod is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, David G. McLeod has authored 271 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 207 papers in Pulmonary and Respiratory Medicine, 54 papers in Surgery and 45 papers in Oncology. Recurrent topics in David G. McLeod's work include Prostate Cancer Treatment and Research (184 papers), Prostate Cancer Diagnosis and Treatment (130 papers) and Urologic and reproductive health conditions (34 papers). David G. McLeod is often cited by papers focused on Prostate Cancer Treatment and Research (184 papers), Prostate Cancer Diagnosis and Treatment (130 papers) and Urologic and reproductive health conditions (34 papers). David G. McLeod collaborates with scholars based in United States, United Kingdom and Denmark. David G. McLeod's co-authors include Judd W. Moul, Shiv Srivastava, Isabell A. Sesterhenn, Mario A. Eisenberger, Brent A. Blumenstein, Joseph T. Spaulding, E. David Crawford, F. Andrew Dorr, Phyllis J. Goodman and Ralph C. Benson and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

David G. McLeod

264 papers receiving 12.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma

1989 1.2k citations David G. McLeod et al. profile →
Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer

1998 685 citations David G. McLeod, George Wilding et al. profile →

Peers

Countries citing papers authored by David G. McLeod

Since Specialization

Citations

This map shows the geographic impact of David G. McLeod's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David G. McLeod with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David G. McLeod more than expected).

Fields of papers citing papers by David G. McLeod

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David G. McLeod. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David G. McLeod. The network helps show where David G. McLeod may publish in the future.

Co-authorship network of co-authors of David G. McLeod

This figure shows the co-authorship network connecting the top 25 collaborators of David G. McLeod. A scholar is included among the top collaborators of David G. McLeod based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David G. McLeod. David G. McLeod is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Filamin A Is a Prognostic Serum Biomarker for Differentiating Benign Prostatic Hyperplasia from Prostate Cancer in Caucasian and African American Men 2024 ·Cancers ·(unknown), (unknown), Matt T. Rosenberg, Albert Dobi, Amina Ali, Gregory M. Miller, Juan J. Aristizabal‐Henao, Elder Granger, Stephen J. Freedland, Mark D. Kellogg, Shiv Srivastava, David G. McLeod, Niven R. Narain, Michael A. Kiebish	2
2	High-throughput optical sensing of peri-cellular oxygen in cardiac cells: system characterization, calibration, and testing 2023 ·Frontiers in Bioengineering and Biotechnology ·(unknown), David G. McLeod, (unknown), (unknown), (unknown), Zhenyu Li, Matthew W. Kay, Emilia Entcheva	2
3	Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth 2018 ·Cancer Research ·Ahmed A. Mohamed, Charles P. Xavier, Gauthaman Sukumar, Shyh‐Han Tan, Lakshmi Ravindranath, (unknown), Vineet Kumar, Taduru Sreenath, David G. McLeod, György Petrovics, Inger L. Rosner, Meera Srivastava, Jeffrey Strovel, Sanjay V. Malhotra, (unknown), Albert Dobi, Clifton L. Dalgard, Shiv Srivastava	44
4	Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells 2017 ·Molecular Cancer Research ·Ahmed A. Mohamed, Shyh‐Han Tan, Charles P. Xavier, Shilpa Katta, Wei Huang, Lakshmi Ravindranath, Muhammad Ameen Jamal, Hua Li, Meera Srivastava, Eri S. Srivatsan, Taduru Sreenath, David G. McLeod, Alagarsamy Srinivasan, György Petrovics, Albert Dobi, Shiv Srivastava	33
5	A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer 2014 ·European Urology ·Jennifer Cullen, Inger L. Rosner, Timothy C. Brand, Nan Zhang, Athanasios C. Tsiatis, Joel T. Moncur, Amina Ali, Yongmei Chen, Dejan Knezevic, Tara Maddala, H. Jeffrey Lawrence, Phillip G. Febbo, Shiv Srivastava, Isabell A. Sesterhenn, David G. McLeod	231
6	Racial/Ethnic Patterns in Prostate Cancer Outcomes in an Active Surveillance Cohort 2011 ·SHILAP Revista de lepidopterología ·Jennifer Cullen, Stephen A. Brassell, Yongmei Chen, Christopher R. Porter, James O. L’Esperance, Timothy C. Brand, David G. McLeod	26
7	Prostate Cancer Risk Allele Specific for African Descent Associates with Pathologic Stage at Prostatectomy 2010 ·Cancer Epidemiology Biomarkers & Prevention ·Eric J. Whitman, Mark M. Pomerantz, Yongmei Chen, (unknown), Bungo Furusato, Chunling Gao, Amina Ali, Lakshmi Ravindranath, Albert Dobi, (unknown), David G. McLeod, Shiv Srivastava, Matthew L. Freedman, György Petrovics	29
8	Longterm Followup Assessment of a HER2/ neu Peptide (E75) Vaccine for Prevention of Recurrence in High-Risk Prostate Cancer Patients 2009 ·Journal of the American College of Surgeons ·Jeremy D. Gates, Mark G. Carmichael, Linda C. Benavides, Jarrod P. Holmes, Matthew T. Hueman, Michael Woll, (unknown), (unknown), David G. McLeod, Sathibalan Ponniah, George E. Peoples	16
9	Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer 2008 ·Clinical Cancer Research ·Ying Hu, Albert Dobi, Taduru Sreenath, Christopher Cook, (unknown), Lakshmi Ravindranath, Jennifer Cullen, Bungo Furusato, Yongmei Chen, Rajesh L. Thangapazham, Ahmed A. Mohamed, Chen Sun, Isabell A. Sesterhenn, David G. McLeod, György Petrovics, Shiv Srivastava	75
10	Higher Expression of the Androgen-Regulated Gene PSA/HK3 mRNA in Prostate Cancer Tissues Predicts Biochemical Recurrence-Free Survival 2008 ·Clinical Cancer Research ·Joseph R. Sterbis, Chunling Gao, Bungo Furusato, Yongmei Chen, Syed Shaheduzzaman, Lakshmi Ravindranath, David Osborn, Inger L. Rosner, Albert Dobi, David G. McLeod, Isabell A. Sesterhenn, Shiv Srivastava, Jennifer Cullen, György Petrovics	18
11	An assessment of the virtual conversations method for prostate cancer patient education. 2007 ·PubMed ·William G. Harless, (unknown), Robert Duncan, (unknown), (unknown), David G. McLeod	6
12	Prostate‐specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer 2007 ·Cancer ·Rinaa S. Punglia, Jennifer Cullen, David G. McLeod, Yongmei Chen, Anthony V. D’Amico	11
13	Higher Tumor to Benign Ratio of the Androgen Receptor mRNA Expression Associates with Prostate Cancer Progression after Radical Prostatectomy 2007 ·Urology ·Inger L. Rosner, Lakshmi Ravindranath, Bungo Furusato, Yongmei Chen, Chunling Gao, Jennifer Cullen, Isabell A. Sesterhenn, David G. McLeod, Shiv Srivastava, György Petrovics	25
14	Quantitative analysis of a panel of gene expression in prostate cancer—with emphasis on NPY expression analysis 2007 ·Journal of Zhejiang University SCIENCE B ·Aijun Liu, Bungo Furusato, Lakshmi Ravindranath, Yongmei Chen, (unknown), David G. McLeod, György Petrovics, Shiv Srivastava	15
15	Vaginal metastasis and thrombocytopenia from renal cell carcinoma 2004 ·Gynecologic Oncology ·(unknown), John W. McBroom, Christopher M. Zahn, David G. McLeod, G. Larry Maxwell	26
16	Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system 2003 ·International Journal of Radiation OncologyBiologyPhysics ·Peter A.S. Johnstone, Robert H. Riffenburgh, Judd W. Moul, Leon Sun, Hongyu Wu, David G. McLeod, Christopher J. Kane, Douglas Martin, Leo Kusuda, Raymond Lance, Robert G. Douglas, Timothy F. Donahue, (unknown), (unknown), Andrew Chung, Douglas W. Soderdahl, (unknown), Christopher L. Amling	25
17	Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients 1997 ·Cancer ·Thomas H. Douglas, Ted O. Morgan, David G. McLeod, Judd W. Moul, Gerald P. Murphy, Robert J. Barren, Isabell A. Sesterhenn, F. K. Mostofi	26
18	Evaluation and comparison of two new prostate carcinoma markers: Free-prostate specific antigen and prostate specific membrane antigen 1996 ·Cancer ·Gerald P. Murphy, Robert J. Barren, Sheila J. Erickson, Victoria Bowes, Robert L. Wolfert, Georg Bartsch, Helmut Klocker, (unknown), Andreas Reissigl, David G. McLeod, Thomas H. Douglas, Ted O. Morgan, Gerald M. Kenny, Haakon Ragde, Alton L. Boynton, Eric H. Holmes	52
19	Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer 1996 ·Surgery ·Judd W. Moul, Marie‐Claude Bettencourt, Isabell A. Sesterhenn, F.K. Mostofi, David G. McLeod, Shiv Srivastava, John J. Bauer	108
20	Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology group 1993 ·Cancer ·(unknown), (unknown), Beow Y. Yeap, George Wilding, Basil Kasimis, David G. McLeod	130

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact